大肠杆菌
苯丙氨酸
微生物学
化学
基因工程
翻译(生物学)
体内
体外
生物化学
细菌
合理设计
酶
输送系统
重组DNA
蛋白质工程
合成生物学
拉伤
定向分子进化
代谢工程
作者
Esse M. Evbuomwan,Sakshi Khanna,Chenggang Xi,Austin G. Rottinghaus,Aura L. Ferreiro,Suryang Kwak,Blake Butler,Jie Ning,Jasmine Najari,James Liao,Harry Diao,Tae Seok Moon,Gautam A. Dantas
标识
DOI:10.1016/j.nbt.2026.09.007
摘要
Engineered probiotics provide new avenues for disease management through diagnostic sensing, delivery of bioactive molecules, and modulation of host-microbiome interactions. However, successful clinical translation requires rational safeguards preventing unintended environmental release. We report an integrated phenylalanine (Phe) sensor and CRISPR-based kill-switch biocontainment system for phenylketonuria (PKU) management. We engineered KSPAL, a strain of Escherichia coli Nissle (EcN) 1917, to sense gut Phe levels and responsively express phenylalanine ammonia lyase (PAL). The kill switch triggers bacterial death below 33°C or upon anhydrotetracycline (aTc) administration, ensuring post-excretion clearance. In vitro, KSPAL demonstrated dose-dependent degradation, achieving more than 60-fold Phe reduction following a 1000 µmol/L Phe spike, and bacterial death upon aTc or temperature induction. In vivo, KSPAL treatment reduced serum Phe by threefold 2-hours post Phe bolus, and KSPAL death 24-hours post aTc induction. This work presents a tunable therapeutic platform for PKU disease management via engineered probiotics.
科研通智能强力驱动
Strongly Powered by AbleSci AI